First Time Loading...

Mayne Pharma Group Ltd
ASX:MYX

Watchlist Manager
Mayne Pharma Group Ltd Logo
Mayne Pharma Group Ltd
ASX:MYX
Watchlist
Price: 7.24 AUD 0.28% Market Closed
Updated: Mar 29, 2024

Intrinsic Value

Mayne Pharma Group Ltd. engages in the development and manufacture of proprietary and generic products. [ Read More ]

The intrinsic value of one MYX stock under the Base Case scenario is 7.56 AUD. Compared to the current market price of 7.24 AUD, Mayne Pharma Group Ltd is Undervalued by 4%.

Key Points:
MYX Intrinsic Value
Base Case
7.56 AUD
Undervaluation 4%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Mayne Pharma Group Ltd

Backtest MYX Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling MYX stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Financials

Balance Sheet Decomposition
Mayne Pharma Group Ltd

Current Assets 475.3m
Cash & Short-Term Investments 154.8m
Receivables 198.9m
Other Current Assets 121.6m
Non-Current Assets 677.3m
PP&E 50.4m
Intangibles 584.6m
Other Non-Current Assets 42.4m
Current Liabilities 295.7m
Accounts Payable 42.8m
Accrued Liabilities 180.1m
Other Current Liabilities 72.8m
Non-Current Liabilities 309.2m
Long-Term Debt 33.1m
Other Non-Current Liabilities 276.1m
Efficiency

Earnings Waterfall
Mayne Pharma Group Ltd

Revenue
278.4m AUD
Cost of Revenue
-89m AUD
Gross Profit
189.5m AUD
Operating Expenses
-286.9m AUD
Operating Income
-97.4m AUD
Other Expenses
-145.9m AUD
Net Income
-243.3m AUD

Free Cash Flow Analysis
Mayne Pharma Group Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

MYX Profitability Score
Profitability Due Diligence

Mayne Pharma Group Ltd's profitability score is 32/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional Revenue Growth Forecast
Exceptional 1-Year Revenue Growth
Negative ROIC
32/100
Profitability
Score

Mayne Pharma Group Ltd's profitability score is 32/100. The higher the profitability score, the more profitable the company is.

MYX Solvency Score
Solvency Due Diligence

Mayne Pharma Group Ltd's solvency score is 57/100. The higher the solvency score, the more solvent the company is.

Negative Net Debt
Low D/E
Long-Term Solvency
Short-Term Solvency
57/100
Solvency
Score

Mayne Pharma Group Ltd's solvency score is 57/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

MYX Price Targets Summary
Mayne Pharma Group Ltd

Wall Street analysts forecast MYX stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MYX is 7.18 AUD with a low forecast of 6.76 AUD and a high forecast of 7.75 AUD.

Lowest
Price Target
6.76 AUD
7% Downside
Average
Price Target
7.18 AUD
1% Downside
Highest
Price Target
7.75 AUD
7% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Shareholder Return

MYX Price
Mayne Pharma Group Ltd

1M 1M
+6%
6M 6M
+123%
1Y 1Y
+99%
3Y 3Y
+16%
5Y 5Y
-41%
10Y 10Y
-53%
Annual Price Range
7.24
52w Low
2.75
52w High
7.24
Price Metrics
Average Annual Return -25.33%
Standard Deviation of Annual Returns 10.3%
Max Drawdown -79%
Shares Statistics
Market Capitalization 588.2m AUD
Shares Outstanding 85 074 304
Percentage of Shares Shorted
N/A

MYX Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Mayne Pharma Group Ltd Logo
Mayne Pharma Group Ltd

Country

Australia

Industry

Pharmaceuticals

Market Cap

588.2m AUD

Dividend Yield

0%

Description

Mayne Pharma Group Ltd. engages in the development and manufacture of proprietary and generic products. The company is headquartered in Adelaide, South Australia. The company went IPO on 2007-06-29. The Company’s segments include Generic Products (GPD), Specialty Products (SPD), Metrics Contract Services (MCS), and Mayne Pharma International (MPI). The GPD segment is engaged in the distribution of generic pharmaceutical products in the United States. GPD segment engaged in the distribution of generic pharmaceutical products in the United States. MCS segment is providing contract pharmaceutical development and manufacturing services to third party customers principally in the United States. SPD segment is distributing specialty pharmaceutical products in the United States. MPI segment manufactures and sells branded and generic pharmaceutical products globally and provisions of contract manufacturing services to third party customers within Australia.

Contact

SOUTH AUSTRALIA
Adelaide
1538 Main North Rd
+61882092666.0
http://www.maynepharma.com/

IPO

2007-06-29

Employees

-

Officers

CEO, MD & Director
Mr. Shawn Patrick O'Brien B.Sc
Chief Financial Officer
Mr. Aaron Gray
Executive VP & General Counsel
Ms. Kimberly Parker J.D.
Executive Vice President of Corporate Development
Mr. Brant Schofield
Director of Global Human Resources
Ms. Erinn Nathaniel
Executive Vice President of Commercial
Mr. Daniel Moore
Show More
Executive VP & Global Chief Medical Officer
Dr. Frank Casty M.D.
Financial Controller
Mr. Brenton Walter
Associate General Counsel & Company Secretary
Ms. Laura Loftus
Show Less

See Also

Discover More
What is the Intrinsic Value of one MYX stock?

The intrinsic value of one MYX stock under the Base Case scenario is 7.56 AUD.

Is MYX stock undervalued or overvalued?

Compared to the current market price of 7.24 AUD, Mayne Pharma Group Ltd is Undervalued by 4%.